Latest Period
Q2 2026
Security Snapshot
Damora Therapeutics, Inc. - Common Stock (DMRA) Institutional Ownership
CUSIP: 36322Q206
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
101
Shares (Excl. Options)
64,442,866
Price
$26.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- DMRA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 64,442,866
- Total 13F value
- $1,672,360,576
- Portfolio coverage rank
- 0%
- Share change
- +8,522,811
- Value change
- +$218,110,714
- Number of holders
- 101
- Shares outstanding
- 61,638,745
- SEC-reported price per share
- $31.48
- Insider filing price
- $31.48
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DMRA - Damora Therapeutics, Inc. - Common Stock is tracked under CUSIP 36322Q206.
- 101 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 64 to 101 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,450,597,849 to $1,672,360,576.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 101 institutions filings for Q2 2026.
Security key
36322Q206
Latest holder period
Q2 2026
13F holders
101
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
DMRA full holder history
Damora Therapeutics, Inc. SEC filings
Damora Therapeutics, Inc. company facts
Damora Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36322Q206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
DMRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $190,117,660 | +$181,455,120 | 8,713,000 | +2095% | Fairmount Funds Management LLC | 09 Feb 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 6% | $78,630,443 | 3,603,595 | Venrock Healthcare Capital Partners III, L.P. | 09 Feb 2026 | |||
| BlackRock, Inc. | 5.1% | $81,748,694 | 3,143,576 | BlackRock, Inc. | 30 Jun 2026 | |||
| FMR LLC | 15% | $6,650,364 | 238,878 | FMR LLC | 28 Nov 2025 | |||
| Paragon Therapeutics, Inc. | 7.5% | $3,494,922 | 120,473 | Paragon Therapeutics, Inc. | 10 Nov 2025 | |||
| Paramora Holding LLC | 7.5% | $3,494,922 | 120,473 | Paramora Holding LLC | 10 Nov 2025 | |||
| Point72 Asset Management, L.P. | 6.3% | $372,164 | 100,001 | Point72 Asset Management, L.P. | 12 Nov 2025 |
As of 30 Jun 2026, 101 institutional investors reported holding 64,442,866 shares of Damora Therapeutics, Inc. - Common Stock (DMRA). This represents 105% of the company’s total 61,638,745 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
95%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 9,232,979 | +2.1% | 0.01% | $240,149,784 |
| Fairmount Funds Management LLC | 14% | 8,713,000 | 0% | 15% | $226,625,130 |
| Avoro Capital Advisors LLC | 6.1% | 3,783,000 | 0% | 0.88% | $98,395,830 |
| Venrock Adviser, LLC | 5.8% | 3,603,595 | 0% | 2.8% | $93,729,506 |
| BlackRock, Inc. | 5.1% | 3,162,068 | +1322% | 0% | $82,245,389 |
| FCPM III SERVICES B.V. | 4% | 2,441,000 | 0% | 8.5% | $63,490,410 |
| RA CAPITAL MANAGEMENT, L.P. | 3.9% | 2,399,702 | +0.02% | 0.54% | $62,416,249 |
| VIKING GLOBAL INVESTORS LP | 3.7% | 2,311,082 | 0% | 0.17% | $60,111,243 |
| Jupiter Topco LLC | 3.7% | 2,282,804 | 0% | 0.02% | $59,284,420 |
| JPMORGAN CHASE & CO | 3.3% | 2,058,933 | 0% | $49,846,768 | |
| Remedium Capital Partners, LLC | 3.3% | 2,045,473 | 0% | 12% | $53,202,753 |
| Commodore Capital LP | 3.1% | 1,939,000 | 0% | 3% | $50,433,390 |
| BRAIDWELL LP | 2.6% | 1,620,377 | +81% | 1.6% | $42,146,006 |
| Bellevue Group AG | 2.6% | 1,618,846 | -30% | 0.89% | $42,106,184 |
| STATE STREET CORP | 2.5% | 1,545,500 | +740% | 0% | $40,198,455 |
| a16z Capital Management, L.L.C. | 2% | 1,236,157 | 0% | 0.23% | $32,152,444 |
| Balyasny Asset Management L.P. | 2% | 1,229,127 | -15% | 0.06% | $31,969,593 |
| PERCEPTIVE ADVISORS LLC | 2% | 1,223,000 | 0% | 0.49% | $31,810,230 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.7% | 1,058,000 | 0% | 0% | $27,518,580 |
| Blackstone Inc. | 1.6% | 1,002,971 | +99% | 0.09% | $26,087,276 |
| Cormorant Asset Management, LP | 1.6% | 1,000,000 | -34% | 1.3% | $26,010,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 965,364 | +300% | 0% | $25,112,228 |
| Siren, L.L.C. | 1.5% | 900,000 | 0% | 0.48% | $23,409,000 |
| UBS Group AG | 1.4% | 840,292 | +424% | 0% | $21,855,995 |
| Vestal Point Capital, LP | 0.93% | 575,000 | -4.2% | 0.35% | $14,955,750 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 64,442,866 | $1,672,360,576 | +$218,110,714 | $26.01 | 101 |
| 2026 Q1 | 55,997,999 | $1,450,597,849 | +$1,414,712,373 | $25.90 | 64 |
| 2025 Q4 | 1,107,880 | $25,492,284 | +$21,929,226 | $23.01 | 18 |
| 2025 Q3 | 170,205 | $633,327 | +$144,879 | $3.72 | 12 |
| 2025 Q2 | 132,660 | $451,146 | -$30,019 | $3.41 | 8 |
| 2025 Q1 | 142,568 | $441,959 | +$1,278 | $3.10 | 10 |
| 2024 Q4 | 142,062 | $660,654 | +$59,803 | $4.65 | 10 |
| 2024 Q3 | 128,626 | $1,562,807 | +$1,556,853 | $12.15 | 9 |